Stock analysts at Jefferies Financial Group began coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) in a report released on Monday,Benzinga reports. The firm set a “buy” rating and a $50.00 price target on the stock. Jefferies Financial Group’s price objective would indicate a potential upside of 73.49% from the stock’s previous close.
Several other equities research analysts have also weighed in on DMRA. Royal Bank Of Canada started coverage on Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They issued an “outperform” rating and a $40.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. HC Wainwright reissued a “buy” rating and issued a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Wedbush restated an “outperform” rating and issued a $35.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, June 12th. Finally, TD Cowen began coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, June 8th. They set a “buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.38.
Check Out Our Latest Analysis on DMRA
Damora Therapeutics, Inc. Common Stock Price Performance
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.23). On average, equities analysts expect that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. Ikarian Capital LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth approximately $6,574,000. Jain Global LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $2,774,000. Remedium Capital Partners LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $2,772,000. Boothbay Fund Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $2,204,000. Finally, Geode Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $266,000. 14.20% of the stock is owned by institutional investors.
About Damora Therapeutics, Inc. Common Stock
Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.
Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.
Recommended Stories
- Five stocks we like better than Damora Therapeutics, Inc. Common Stock
- These 3 AI Winners Don’t Sell the Tech—They Use It
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
Receive News & Ratings for Damora Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Damora Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
